The data indicates that restoring Par-4 levels in cancer cells by using small molecule secretagogues like Ketorolac would not only lead to inhibition of angiogenic factors like HIF-1α and VEGF but also inhibition of cell growth, migration/invasion, polarity, adhesion, and cytoskeletal rearranging markers viz. The gene discussed is HIF1A; the disease is cancer.